D. Hosking

发表

Effects of Risedronate Treatment on Bone Density and Vertebral Fracture in Patients on Corticosteroid Therapy

D. Reid, Janet E Brown, S. Wallach, 2000, Calcified Tissue International.

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age.

C. Christiansen, P. Ross, C. Chilvers, 1998 .

Association between a family history of fractures and bone mineral density in early postmenopausal women.

C. Coupland, D. Hosking, C. Chilvers, 1999, Bone.

Zoledronate.

S. Cummings, I. Reid, D. Reid, 2020, Bone.

Changes in Total Body Calcium and Sodium in Osteomalacia

D. Hosking, M. Chamberlain, J. Fremlin, 1972, British medical journal.

Low Body Mass Index Is an Important Risk Factor for Low Bone Mass and Increased Bone Loss in Early Postmenopausal Women

C. Christiansen, R. Wasnich, D. Hosking, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Cross‐Sectional Analysis of Renal Transplantation Osteoporosis

A. Freemont, D. Hosking, M. Grainge, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Clinical usefulness of risk factors for osteoporosis.

D. Hosking, S. Earnshaw, 1996, Annals of the rheumatic diseases.

Strategy for the Management of Osteoporosis

D. Hosking, O. Sahota, C. Parker, 1997 .

Is Macrosomia Associated with Poor Glycaemic Control in Diabetic Pregnancy?

D. Hosking, R. Page, T. Fay, 1996, Diabetic medicine : a journal of the British Diabetic Association.

A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NONOF) Study.

R. Harwood, D. Hosking, T. Masud, 2004, Age and ageing.

Oral antiresorptive therapy.

D. Hosking, I. Pande, 2004 .

Oral antiresorptive therapy

D. Hosking, I. Pande, 2004, Current osteoporosis reports.

A multicenter study of the influence of fat and lean mass on bone mineral content: evidence for differences in their relative influence at major fracture sites. Early Postmenopausal Intervention Cohort (EPIC) Study Group.

P. Ross, J. Davis, R. Wasnich, 1996, The American journal of clinical nutrition.

Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study

J. Reginster, D. Felsenberg, M. Välimäki, 2003, Current medical research and opinion.

Meeting report from the IOF world congress on osteoporosis

C. Cooper, J. Eisman, G. Rodan, 2002 .

Diagnosis and treatment of prostatitis in Canada.

L. Valiquette, D. Hosking, J. Nickel, 1998, Urology.

A UK Consensus Group on management of glucocorticoid‐induced osteoporosis: an update

C. Cooper, R. Francis, D. Torgerson, 1998, Journal of internal medicine.

Alendronate Sodium in the Management of Osteoporosis

D. Hosking, P. Prinsloo, D. Hosking, 2006, Therapeutics and clinical risk management.

Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study.

C. Christiansen, P. Ross, D. Hosking, 2004, The Journal of clinical endocrinology and metabolism.

Treatment of SAPHO with pamidronate.

D. Hosking, C. Deighton, P. Courtney, 2002, Rheumatology.

Evidence that increased calcium intake does not prevent early postmenopausal bone loss.

P. Ross, D. Hosking, M. McClung, 1998, Clinical therapeutics.

A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24‐month results from FACTS‐International

D. Reid, J. Wark, M. Brandi, 2008, International journal of clinical practice.

Osteoporosis therapy: an example of putting evidence-based medicine into clinical practice.

P. Geusens, R. Rizzoli, D. Hosking, 2005, QJM : monthly journal of the Association of Physicians.

Management of corticosteroid-induced osteoporosis.

D. Hosking, S. Yeap, 2002, Rheumatology.

Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis

M. Hochberg, L. Wehren, D. Hosking, 2004, Current medical research and opinion.

Colles' Fracture of the Wrist as an Indicator of Underlying Osteoporosis in Postmenopausal Women: A Prospective Study of Bone Mineral Density and Bone Turnover Rate

D. Hosking, S. Earnshaw, S. Cawte, 1998, Osteoporosis International.

Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget’s disease

I. Reid, D. Hosking, P. Selby, 2008, Osteoporosis International.

Baroreflex sensitivity and responses to the Valsalva manoeuvre in subjects with diabetes mellitus.

J. Hampton, D. Hosking, T. Bennett, 1976, Journal of neurology, neurosurgery, and psychiatry.

Baroreflex sensitivity andresponsestotheValsalva manoeuvreinsubjects withdiabetes mellitus

J. Hampton, D. Hosking, T. Bennett, 1976 .

The contribution of bone densitometry to the diagnosis and treatment of osteoporosis.

C. Coupland, D. Hosking, C. Chilvers, 1997, Public health.

Alendronic Acid Produces Greater Effects than Risedronic Acid on Bone Density and Turnover in Postmenopausal Women with Osteoporosis

D. Reid, J. Wark, M. Brandi, 2006, Clinical drug investigation.

Esophageal transit of the weekly film-coated risedronate (Actonel) placebo tablet in subjects with Kyphosis.

R. Spiller, A. Perkins, D. Hosking, 2006, International journal of pharmaceutics.

Paget's disease of bone: reduction of disease activity with oral risedronate.

D. Hosking, A. Chines, R. Eusebio, 1998, Bone.

Hyperparathyroidism in the Elderly Patient

D. Hosking, C. Ubhi, R. Sims, 2004, Drugs & aging.

An audit of current clinical practice in the management of osteoporosis in Nottingham.

D. Hosking, O. Sahota, A. Worley, 2000, Journal of public health medicine.

Tooth counts do not predict bone mineral density in early postmenopausal Caucasian women. EPIC study group.

D. Hosking, M. McClung, C. Chilvers, 1998, International journal of epidemiology.

Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study.

D. Hosking, C. Parker, P. Blackwell, 2002, The Journal of clinical endocrinology and metabolism.

Treatment of osteoporosis: bisphosphonates as an alternative to hormone replacement therapy

D. Hosking, C. Parker, 1996 .

Treatment of osteoporosis: current and future.

D. Hosking, M. Stone, 1991, Annals of the rheumatic diseases.

Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate.

G. Mundy, D. Hosking, C. Reasner, 1993, The Journal of clinical endocrinology and metabolism.

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.

P. Geusens, J. Kaufman, P. Jaeger, 1996, Bone.

Biochemical measurements in the prediction of histologic subtype of renal transplant bone disease in women.

A. Freemont, D. Hosking, C. Parker, 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial.

W. Murphy, I. Reid, R. Weinstein, 1996, The American journal of medicine.

Recovery of pregnancy mediated bone loss during lactation.

P. Baker, N. Lawson, D. Hosking, 2004, Bone.

Relationship between vitamin D status, parathyroid hormone levels and bone mineral density in patients with chronic kidney disease stages 3 and 4

D. Hosking, A. Stavroulopoulos, C. Porter, 2007, Nephrology.

Vitamin D Status in Renal Transplant Recipients

D. Hosking, A. Stavroulopoulos, C. Porter, 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Longitudinal changes in bone mineral density during normal pregnancy.

N. Lawson, D. Hosking, I. Godber, 2003, Bone.

The relationship between bone mineral density and ultrasound in postmenopausal and osteoporotic women

D. Hosking, S. Yeap, S. Cawte, 2007, Osteoporosis International.

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three‐year continued therapy and resolution of effect

R. Rizzoli, I. Reid, J. Eisman, 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Genetic and environmental factors affecting bone mineral density in large families.

D. Hosking, S. Yeap, M. Beaumont, 1998, Postgraduate medical journal.

Relation between body composition and biochemical markers of bone turnover among early postmenopausal women.

P. Ross, J. Davis, R. Wasnich, 2000, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Occupational Activity and Bone Mineral Density in Postmenopausal Women in England

C. Coupland, D. Hosking, C. Chilvers, 2000, Osteoporosis International.

Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study.

C. Christiansen, D. Hosking, M. McClung, 1999, The Journal of clinical endocrinology and metabolism.

Advances in the Management of Paget’s Disease of Bone

D. Hosking, 1990, Drugs.

Paget’s Disease of Bone

D. Hosking, 1981, Drugs.

Changes in Osteocalcin after Femoral Neck Fracture

D. Hosking, D. White, T. Wilton, 1989, Annals of clinical biochemistry.

Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study.

P. Richardson, E. Siris, D. Hosking, 1999, Bone.

Calcium excretion (CaE) in metastatic breast cancer

R. Blamey, C. Elston, F. Campbell, 1983, The British journal of surgery.

Cardiovascular reflex responses to apnoeic face immersion and mental stress in diabetic subjects.

J. Hampton, D. Hosking, T. Bennett, 1976, Cardiovascular research.

Vitamin D insufficiency and the blunted PTH response in established osteoporosis: the role of magnesium deficiency

D. Hosking, O. Sahota, M. Mundey, 2006, Osteoporosis International.

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

C. Christiansen, P. Ross, C. Chilvers, 1998, The New England journal of medicine.

Review Medical Management of Hypercalcemia

E. McCloskey, S. Ralston, W. Fraser, 2004 .

Medical Management of Hypercalcemia

E. McCloskey, S. Ralston, W. Fraser, 2003, Calcified Tissue International.

Rehydration in the treatment of severe hypercalcaemia.

D. Hosking, A. Cowley, C. Bucknall, 1981, The Quarterly journal of medicine.

Serial assessment of serum calcium correlates with mental state

D. Hosking, E. Byrne, C. Jameson, 1987 .

Osteomalacia and carcinoma of prostate with major redistribution of skeletal calcium.

D. Hosking, M. Chamberlain, W. Shortland-Webb, 1975, The British journal of radiology.

Effect of bendrofluazide on calcium reabsorption in hypoparathyroidism

G. H. Newman, D. Hosking, M. Wade, 2004, European Journal of Clinical Pharmacology.

Effect of bendrofluazide on calcium reabsorption in hypoparathyroidism

G. H. Newman, D. Hosking, M. Wade, 2004, European Journal of Clinical Pharmacology.

Renal handling of calcium in hypoparathyroidism.

G. H. Newman, D. Hosking, M. Wade, 1983, British medical journal.

Oesophageal motor changes in diabetes mellitus.

D. Hosking, I. Stewart, B. Preston, 1976, Thorax.

Safety of treatment for subclinical osteomalacia in the elderly.

D. Hosking, J. Kemm, R. E. Cotton, 1984, British medical journal.

Management of osteoporosis with PTH: treatment and prescription patterns in Europe.

M. Brandi, D. Hosking, C. G. Alonso, 2009, Current medical research and opinion.

Gastrointestinal complications of diabetes mellitus.

D. Hosking, M. Atkinson, 1983, Clinics in gastroenterology.

Are calcium supplements necessary in vitamin-D-replete individuals?

D. Hosking, 2006, Nature Clinical Practice Endocrinology &Metabolism.

The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis.

N. Lawson, D. Hosking, O. Sahota, 2004, Bone.

Reduced bone mineral density in male renal transplant recipients: evidence for persisting hyperparathyroidism

D. Hosking, C. Porter, I. Godber, 2005, Osteoporosis International.

Vitamin D insufficiency increases bone turnover markers and enhances bone loss at the hip in patients with established vertebral osteoporosis

D. Hosking, T. Masud, O. Sahota, 1999, Clinical endocrinology.

Quantitation of the renal effect of calcitonin in the hypercalcaemia of malignancy

D. Hosking, S. Heller, 2004, European Journal of Clinical Pharmacology.

Hypovitaminosis D and 'functional hypoparathyroidism'-the NoNoF (Nottingham Neck of Femur) study.

R. Harwood, D. Hosking, O. Sahota, 2001, Age and ageing.

Correction of vitamin D deficiency in elderly long-stay patients by sunlight exposure.

M. Steven, A. Webb, D. Hosking, 1990 .

A single infusion of zoledronic acid produces sustained remissions in paget disease: Data to 6.5 years

Jacques P. Brown, I. Reid, P. Miller, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

Jacques P. Brown, I. Reid, P. Miller, 2005, The New England journal of medicine.

The contribution of nutritional factors to osteopenia in the elderly

D. Hosking, O. Sahota, 2001, Current opinion in clinical nutrition and metabolic care.

Osteoporosis and Long-term Corticosteroid Therapy

D. Hosking, M. Chamberlain, 1973, British medical journal.

The management of primary hyperparathyroidism

W. Fraser, D. Hosking, M. Davies, 2002, Clinical endocrinology.

Is vitamin D necessary for skeletal integrity in the elderly?

D. Hosking, D. White, T. Wilton, 1990, The Journal of bone and joint surgery. British volume.

Effects of corticosteroids on bone turnover.

D. Hosking, 1993, Respiratory medicine.

Medical management of primary hyperparathyroidism

D. Hosking, 2013 .

Vasomotor responses to the Valsalva manoeuvre in normal subjects and in patients with diabetes mellitus.

J. Hampton, D. Hosking, T. Bennett, 1979, British heart journal.

A neuroendocrine cause of oncogenic osteomalacia

D. Hosking, C. Quincey, M. Stone, 1992, The Journal of pathology.

SCREENING FOR SUBCLINICAL OSTEOMALACIA IN THE ELDERLY: NORMAL RANGES OR PRAGMATISM?

D. Hosking, J. Kemm, R. E. Cotton, 1983, The Lancet.

Changes in serum markers of bone turnover during normal pregnancy

N. Lawson, D. Hosking, I. Godber, 2003, Annals of clinical biochemistry.

bone mineral density in large families . Genetic and environmental factors affecting

D. Hosking, S. Yeap, M. Beaumont, 2008 .

HOW COMMON IS OSTEOMALACIA IN THE ELDERLY?

D. Hosking, J. Kemm, R. Boyd, 1984, The Lancet.

A Pragmatic Approach to Sexual Dysfunction in Diabetic Men: Psychosexual Counselling

D. Hosking, D. McCulloch, A. Tobert, 1986, Diabetic medicine : a journal of the British Diabetic Association.

Longitudinal changes of insulin-like growth factors and their binding proteins throughout normal pregnancy

N. Lawson, D. Hosking, J. Monaghan, 2004, Annals of clinical biochemistry.

The renal response to exogenous parathyroid hormone in treated pseudohypoparathyroidism.

D. Hosking, D. White, H. Worth, 1993, Bone.

Vagal impairment of gastric secretion in diabetic autonomic neuropathy.

D. Hosking, F. Moody, I. Stewart, 1975, British medical journal.

Bisphosphonates in Paget's disease.

I. Reid, D. Hosking, 2011, Bone.

Screening for osteomalacia in elderly patients with femoral neck fractures.

D. Hosking, T. Wilton, L. Harvey, 1987, The Journal of bone and joint surgery. British volume.

Changes in serum alkaline phosphatase after femoral fractures.

D. Hosking, 1978, The Journal of bone and joint surgery. British volume.

Calcium homeostasis in pregnancy

D. Hosking, 1996, Clinical endocrinology.

Osteomalacia and femoral neck fractures in the elderly patient.

D. Hosking, T. Wilton, L. Harvey, 1987, The Journal of bone and joint surgery. British volume.

Rescue of trophoblast apoptosis by parathyroid hormone‐related protein

I. Crocker, P. Baker, D. Hosking, 2002, BJOG : an international journal of obstetrics and gynaecology.

Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy.

D. Hosking, D. Gilson, 1984, The Quarterly journal of medicine.

Risedronate, a Highly Effective, Short-Term Oral Treatment for Paget's Disease: A Dose-Response Study

J. Reginster, D. Hosking, P. Bekker, 1999, Calcified Tissue International.

Update on calcium and vitamin D metabolism

D. Hosking, O. Sahota, 1999 .

Potentiation of calcitonin by corticosteroids during the treatment of the hypercalcaemia of malignancy

D. Hosking, M. Stone, J. Foote, 2004, European Journal of Clinical Pharmacology.

SCREENING FOR VITAMIN D DEPLETION

D. Hosking, R. Boyd, G. Campbell, 1984, The Lancet.

Declaration on Vitamin D in Osteoporosis Management: From the European Summit on the Role of Vitamin D in the Management of Osteoporosis: a MetaForum.

L. Mosekilde, M. Brandi, D. Hosking, 2007, Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases.

Diabetic impotence: studies of nocturnal erection during REM sleep.

J. Hampton, D. Hosking, G. Robertson, 1979, British medical journal.

Comparison of low-dose intramuscular and intravenous salcatonin in the treatment of primary hyperparathyroidism.

D. Hosking, D. Marshall, D. White, 1992, Bone.

Changes in total body calcium content in primary hyperparathyroidism.

D. Hosking, M. Chamberlain, J. Fremlin, 1972, Clinical science.

Comparison of intact and 'whole molecule' parathyroid hormone assays in patients with histologically confirmed post-renal transplant osteodystrophy

N. Lawson, D. Hosking, C. Porter, 2002, Annals of clinical biochemistry.

RHEUMATIC DISEASES Leaders Treatment of osteoporosis : current and future

D. Hosking, M. Stone, 2022 .

Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone.

G D Roodman, N. Kurihara, D. Hosking, 1992, The Journal of clinical investigation.

Treatment of Paget's disease with combined calcitonin and diphosphonate (EHDP)

D. Hosking, O. Bijvoet, J. Velde, 1978 .

Ten years' experience with alendronate for osteoporosis in postmenopausal women.

J. Rodriguez-Portales, U. Liberman, D. Hosking, 2004, The New England journal of medicine.

Current diet does not relate to bone mineral density after the menopause

D. Hosking, S. Earnshaw, A. Worley, 1997, British Journal of Nutrition.

Diabetic Autonomic Neuropathy

J. Hampton, D. Hosking, T. Bennett, 1978, Diabetes.

Calcitonin and diphosphonate in the treatment of Paget's disease of bone.

D. Hosking, 1981, Metabolic bone disease & related research.

Biochemical Assessment of Paget's Disease of Bone

D. Hosking, S. Shankar, 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Out-patient hysteroscopy in asymptomatic postmenopausal women.

D. Hosking, T. Fay, N. Khanem, 1999, Climacteric : the journal of the International Menopause Society.

Abnormalities in osteoclast precursors and marrow accessory cells in Paget's disease.

G. Roodman, D. Hosking, F. Singer, 1993, Endocrinology.

A Potential Autocrine/Paracnne Factor in Paget's Disease of Bone

D. Hosking, F. Singer, A. Kukita, 1992 .

Assessment of vagal control of the heart in diabetes. Measures of R-R interval variation under different conditions.

J. Hampton, D. Hosking, P. Fentem, 1977, British heart journal.

Disequilibrium hypercalcaemia.

D. Hosking, 1983, British medical journal.

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience.

C. Cooper, J. Reginster, D. Mellström, 2003, Bone.

The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation

J. Chandler, P. Lips, D. Hosking, 2006, Journal of internal medicine.

Quantitative bone scintigraphy in the management of monostotic Paget's disease of bone.

D. Hosking, S. Patel, D. Pearson, 1995, Arthritis and rheumatism.

Paget's disease of bone: an endocrine society clinical practice guideline.

I. Reid, M. Murad, E. Siris, 2014, The Journal of clinical endocrinology and metabolism.

Response to letter by Ralston et al.

I. Reid, E. Siris, D. Hosking, 2015, Journal of Clinical Endocrinology and Metabolism.

Paget's disease of bone: a review of 889 patients.

R. Francis, R. Tansley, D. Hosking, 1999, Bone.

PAGET'S BONE DISEASE TREATED WITH DIPHOSPHONATE AND CALCITONIN

D. Hosking, E. Will, O. Bijvoet, 1976, The Lancet.

Fortnightly Review: Paget's disease of bone: diagnosis and management

J. Reginster, D. Hosking, P. Meunier, 1996, BMJ.

Comparison of methods of assessing response of Paget's disease to bisphosphonate therapy.

C. Coupland, D. Hosking, S. Patel, 1995, Bone.

Determinants of remission of paget's disease of bone

C. Coupland, D. Hosking, Sanjeev Patel, 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Bone scintigraphy in Paget's disease treated with combined calcitonin and diphosphonate (EHDP).

E. Pauwels, D. Hosking, O. Bijvoet, 1982, Metabolic bone disease & related research.

Evaluation of scintigraphic and roentgenologic studies in Paget's disease under treatment.

E. Pauwels, D. Hosking, O. Bijvoet, 1976, Radiologia clinica.

Long‐Term Control of Bone Turnover in Paget's Disease With Zoledronic Acid and Risedronate

Jacques P. Brown, I. Reid, P. Miller, 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Management of fissure fractures in Paget's disease

W. Vennart, D. Hosking, J. Redden, 2004, International Orthopaedics.

Biochemical response to combination of disodium etidronate with calcitonin in Paget's disease.

D. Hosking, D. O'donoghue, 1987, Bone.

Changes in bone mineral density in patients with Paget’s disease treated with risedronate

D. Hosking, Sanjeev Patel, D. Pearson, 1997, Annals of the rheumatic diseases.

Pharmacological therapy of Paget's and other metabolic bone diseases.

D. Hosking, 2006, Bone.

Drugs Used in the Treatment of Metabolic Bone Disease

D. Hosking, Sanjeev Patel, A. Lyons, 1993, Drugs.

Paget's disease of bone.

D. Hosking, 1981 .

Resistance to celcifin daring the treatment of paget's disease

T. Martin, D. Hosking, L. Huddlestone, 1981 .

Osteomalacia presenting as chorea.

R. Godwin-Austen, D. Hosking, S. Allison, 1975, British medical journal.

Prediction and assessment of the response of Paget's disease to bisphosphonate treatment.

D. Hosking, 1999, Bone.

Treatment of paget's disease with intermittent low‐dose infusions of disodium pamidronate (APD)

D. Hosking, A. Hawthorne, M. Stone, 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Hypoparathyroidism and Addison's Disease: A Potentially Lethal Combination

W. Jeffcoate, D. Hosking, R. Jones, 1987, Journal of the Royal Society of Medicine.

Cardiovascular control in diabetes mellitus.

J. Hampton, D. Hosking, T. Bennett, 1975, British medical journal.

Management of severe hypercalcaemia.

D. Hosking, 1980, British medical journal.

Changes in bone density and turnover after alendronate or estrogen withdrawal

C. Christiansen, Y. Bagger, P. Alexandersen, 2004, Menopause.

The use of a whole body index with bone scintigraphy to monitor the response to therapy in Paget's disease

D. Hosking, C. Parker, R. Vincent, 2001, Nuclear medicine communications.

The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis.

S. Sen, D. Hosking, S. Gaugris, 2007, QJM : monthly journal of the Association of Physicians.

Management of male osteoporosis: report of the UK Consensus Group.

C. Cooper, R. Francis, R. Eastell, 1998, QJM : monthly journal of the Association of Physicians.

Self-administered subcutaneous fluid infusion at home in the management of fluid depletion and hypomagnesaemia in gastro-intestinal disease.

D. Hosking, S. Allison, J. Kendall, 2005, Clinical nutrition.

Proceedings: Impairment of upper alimentary vagal function in diabetes.

D. Hosking, I. Stewart, B. Preston, 1974, Gut.

Management of osteoporosis with PTH: treatment and prescription patterns in Europe

M. Brandi, D. Hosking, C. G. Alonso, 2009 .

Paget's disease ofbone

D. Hosking, 1981 .

diabetes mellitus . Oesophageal motor changes in

D. Hosking, I. Stewart, B. Preston, 2022 .

Cardiovascular responses to lower body negative pressure in normal subjects and in patients with diabetes mellitus.

J. Hampton, D. Hosking, T. Bennett, 1979, Cardiovascular research.

Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action?

C. Cooper, R. Francis, R. Eastell, 2001, QJM : monthly journal of the Association of Physicians.

Fluoride pharmacokinetics and changes in lumbar spine and hip bone mineral density.

D. Hosking, S. Patel, J. K. Chan, 1996, Bone.

Studies in man with 18F.

D. Hosking, M. Chamberlain, 1972 .

Reproductive, Menstrual and Menopausal Factors: Which Are Associated with Bone Mineral Density in Early Postmenopausal Women?

C. Coupland, C. Chilvers, D. Hosking, 2001, Osteoporosis International.

The Ideal Drug for Treatment of Osteoporosis

D. Hosking, 2007 .

FUNCTIONAL SIGNIFICANCE OF ANTIBODY FORMATION AFTER LONG‐TERM SALMON CALCITONIN THERAPY

D. Hosking, B. Cadge, T. J. Martin, 1979, Clinical endocrinology.

Mechanisms of parathyroid hormone resistance in pseudohypoparathyroidism.

D. Hosking, D. Kerr, 1988, Clinical science.

The diphosphonate space: a useful quantitative index of disease activity in patients undergoing hexamethylene diphosphonate (HMDP) bone imaging for Paget's disease

A. Perkins, D. Hosking, M. Wastie, 2004, European Journal of Nuclear Medicine.

The diphosphonate space: a useful quantitative index of disease activity in patients undergoing hexamethylene diphosphonate (HMDP) bone imaging for Paget's disease

A. Perkins, D. Hosking, M. Wastie, 2004, European Journal of Nuclear Medicine.

Bisphosphonate Space Measurement in Paget's Disease of Bone Treated with APD

A. Perkins, D. Hosking, D. Marshall, 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Cigarette Smoking, Alcohol and Caffeine Consumption, and Bone Mineral Density in Postmenopausal Women

C. Coupland, D. Hosking, C. Chilvers, 1998, Osteoporosis International.

Renal handling of calcium and sodium in metastatic and non-metastatic malignancy.

D. Hosking, S. Heller, 1986, British medical journal.

Studies in man with 18 F.

D. Hosking, M. Chamberlain, 1972, Clinical science.

A comparison of calcaneal dual-energy X-ray absorptiometry and calcaneal ultrasound for predicting the diagnosis of osteoporosis from hip and spine bone densitometry.

D. Hosking, T. Masud, O. Sahota, 2003, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Calcium Balance in Chronic Renal Failure

D. Hosking, M. Chamberlain, 1973 .

Calcium balance in chronic renal failure. A study using in vivo neutron activation analysis.

D. Hosking, M. Chamberlain, 1973, The Quarterly journal of medicine.

A Comparison of the Longitudinal Changes in Quantitative Ultrasound with Dual-Energy X-ray Absorptiometry: The Four-Year Effects of Hormone Replacement Therapy

D. Hosking, O. Sahota, S. Cawte, 2000, Osteoporosis International.

Once weekly alendronate produces a greater increase in bone mineral density than daily risedronate

J. Reginster, D. Felsenberg, M. Välimäki, 2003 .

Diabetic autonomic neuropathy.

J. Hampton, D. Hosking, T. Bennett, 1986, Diabetes.

Sustained fracture benefit with five years of risedronate in postmenopausal women

J. Reginster, D. Hosking, S. Adami, 2001 .